Pharma BD Deal Intelligence
A first-in-class ROR1-targeted antibody-drug conjugate that Merck bought for $2.75 billion and is now paying off: zilovertamab vedotin posted a 100% complete response rate in frontline diffuse large B-cell lymphoma, propelling it into a ~1,046-patient Phase 3 trial, though it must still win share in a crowded field against CD20xCD3 bispecifics and CAR-T.
Merck acquired VelosBio for $2.75B for antibody-drug conjugate targeting ROR1.
Merck announced initiation of the Phase 3 waveLINE-010 trial evaluating zilovertamab vedotin plus R-CHP vs R-CHOP in ~1,046 previously untreated DLBCL patients.
Merck to acquire VelosBio for $2.75 billion in cash, gaining VLS-101, a first-in-class antibody-drug conjugate targeting ROR1 for hematologic malignancies and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Merck (NYSE: MRK) acquired VelosBio for $2.75 billion in cash, with the deal announced November 5, 2020 and completed December 18, 2020. The acquisition gave Merck VelosBio's lead asset, zilovertamab vedotin (VLS-101 / MK-2140), a first-in-class investigational antibody-drug conjugate targeting ROR1, a receptor tyrosine kinase-like orphan receptor expressed across hematologic and solid tumors. As of 2025 the program has advanced to pivotal development on the strength of Phase 2 data: the Phase 2 waveLINE-007 trial reported a 100% complete response rate at the 1.75 mg/kg dose in previously untreated diffuse large B-cell lymphoma (DLBCL) (Merck, Dec 2024), prompting initiation of the Phase 3 waveLINE-010 trial (zilovertamab vedotin plus R-CHP vs R-CHOP, ~1,046 patients) in frontline DLBCL in February 2025. In relapsed/refractory DLBCL, the Phase 2 portion of waveLINE-003 showed a 56.3% objective response rate with R-GemOx (ASCO 2025), with the study advancing to its Phase 3 portion. The ROR1 ADC enters a crowded B-cell lymphoma landscape contested by CD20xCD3 bispecifics, CD19 CAR-T, and competing ADCs.
Zilovertamab vedotin (MK-2140) targets ROR1 in R/R DLBCL and must displace entrenched incumbents across four MOA classes. ADCs with non-ROR1 targets: Polivy (polatuzumab vedotin, Roche) CD79b-MMAE ADC is approved with R-CHP in 1L DLBCL based on POLARIX (NEJM 2022) and is now the 1L SOC in higher-risk IPI patients; Zynlonta (loncastuximab tesirine, ADC Therapeutics) CD19-PBD ADC approved 3L+ DLBCL. Autologous CD19 CAR-T: Yescarta (axicabtagene ciloleucel, Kite/Gilead) and Breyanzi (lisocabtagene maraleucel, BMS) are approved in 2L R/R LBCL after ZUMA-7 and TRANSFORM respectively, displacing auto-HSCT; Kymriah (tisagenlecleucel, Novartis) remains 3L+. CD20xCD3 bispecifics: Columvi (glofitamab, Roche) fixed-duration and Epkinly (epcoritamab, AbbVie/Genmab) continuous dosing approved in 3L+ R/R DLBCL with response rates in the 40-60% range and growing penetration in community/academic mix. Chemoimmunotherapy backbone: R-CHOP with rituximab biosimilars remains 1L foundation. Merck reported advancing zilovertamab vedotin into Phase 3 waveLINE-007/010 in frontline and R/R DLBCL. Commercial threat is the collapse of post-CAR-T white space due to bispecific uptake, plus Polivy front-line fortification. ROR1 must differentiate in bispecific-refractory, high-risk biology, or combinations with Keytruda.
Zilovertamab vedotin (MK-2140) is a Phase 2/3 ROR1-targeted MMAE ADC; it enters a densely contested B-cell lymphoma landscape spanning five MOA classes. CD19-directed ADCs/bispecifics/CAR-T: Polivy (polatuzumab vedotin, Roche) CD79b ADC is approved with R-CHP in 1L DLBCL (POLARIX), competing as an ADC benchmark; Zynlonta (loncastuximab tesirine, ADC Therapeutics) CD19 ADC approved in 3L+ DLBCL; Yescarta (axicabtagene ciloleucel, Kite/Gilead), Breyanzi (lisocabtagene maraleucel, BMS), and Kymriah (tisagenlecleucel, Novartis) anchor CAR-T in R/R LBCL. CD20xCD3 bispecifics: Columvi (glofitamab, Roche), Epkinly (epcoritamab, AbbVie/Genmab), and Lunsumio (mosunetuzumab, Roche) are approved in R/R DLBCL/FL and are the fastest-growing class. BTK inhibitors: Imbruvica (ibrutinib, J&J/AbbVie, roughly $9B global), Calquence (acalabrutinib, AstraZeneca, $2.5B+), Brukinsa (zanubrutinib, BeiGene, rapid growth) and Jaypirca (pirtobrutinib, Lilly) span MCL, CLL, WM. BCL-2: Venclexta (venetoclax, AbbVie/Roche) anchors CLL frontline. Anti-CD20 backbone: Rituxan (rituximab) biosimilars universal. Commercial threat for zilovertamab vedotin is crowding from CD20xCD3 bispecifics and Polivy expansion; ROR1 selectivity needs to carve space in post-CAR-T/post-bispecific settings.
Merck completed $2.75B acquisition of VelosBio, gaining VLS-101 antibody-drug conjugate targeting ROR1 for hematologic and solid tumors.
Merck continued clinical development of ROR1-targeted ADC (MK-2140) in combinations, though slower progress than initially anticipated.
Zilovertamab vedotin (MK-2140) plus R-CHP achieved a 100% complete response rate at the 1.75 mg/kg dose in the Phase 2 waveLINE-007 trial of previously untreated DLBCL, supporting advancement to Phase 3.
Merck initiated the Phase 3 waveLINE-010 trial evaluating zilovertamab vedotin plus R-CHP vs R-CHOP in ~1,046 previously untreated DLBCL patients — the ROR1 ADC's first pivotal study, validating the VelosBio thesis.
ROR1 ADC zilovertamab vedotin (MK-2140) has advanced to pivotal development: Phase 2 waveLINE-007 reported 100% CR in 1L DLBCL, triggering the Phase 3 waveLINE-010 trial (Feb 2025), while waveLINE-003 (R/R DLBCL, 56.3% ORR) moves to Phase 3. Program de-risked vs. 2023; registrational readout and a contested B-cell lymphoma landscape remain the open questions.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / VelosBio Inc. (this deal) | 2020 | $2.8B | 62 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2020 deals · Merck & Co. Inc. deals · Oncology deals